The management of unresectable hepatocellular carcinoma (HCC) involves recognizing and managing adverse events and effectively working with a multidisciplinary team. This Clinical ForumSM brings together an interventional radiologist, oncologist, and hepatologist to discuss how they work together at their institutions to achieve a common goal.
Upon completion of this activity, participants should be better able to:
Memorial Sloan Kettering Cancer Center
New York, NY
Memorial Hospital for Cancer and Allied Diseases
New York, NY
David Bruton Jr. Professor in Clinical Cancer Research
Associate Professor, Medicine
Medical Director, Liver Tumor Program
Clinical Chief, Hepatology
University of Texas Southwestern
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources